Non-Dilutive Investment and Product License Includes Licensing Fee and Development Costs

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / August 27, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, signed a definitive agreement effective August 10th, 2018 with Nico Innovagroup S.r.l. with its principal headquarters in Brescia, Italy. The definitive agreement encompasses the license of the company’s liquid insulin mouth rinse solution for a period of 15 years in the European market in exchange for milestone payments and a royalty up to a 10% of the drug sales.

The terms of the definitive agreement mirror the previously announced Memorandum of Understanding and are related to the European licensing and distribution of the liquid insulin mouth rinse. The European license included 28 countries. Additionally, Nico Innovagroup will be responsible for the manufacturing and distribution of EastGate’s nutraceutical products. Nico Innovagroup’s licensing agreement is assignable, and Nico Innovagroup is already proceeding to transfer the agreement to the new incorporated subsidiary company Nico Innovapharma S.r.l., that will operate with a consortium of several mid-sized European pharmaceutical companies with the aim to approach much larger pharmaceuticals and to form a distribution framework capable of quickly bringing to market the oral insulin mouth rinse after receiving regulatory approval.

According to the terms of the definitive agreement, milestone payments will commence immediately.

1. The first milestone payment is an equity offering for 2.0 million preferred stock with priority position in the intellectual property of the liquid insulin mouth rinse. The preferred stock pays no dividend and simply gives the preferred shareholders priority treatment in the event of dissolution of the company and is convertible into common on a 1 for 1 basis. $2.0 million is due within 60 days of signing in exchange for 2.0 million preferred shares of ETBI at a price of $1.00/ share.

2. $8.0 million upon the successful completion of a phase 2 study on the liquid insulin mount rinse from the Philippines or any other market in which EastGate or is partner are able to conduct a trial.

3. $20 million investment for the purposes of funding the clinical trial expenses necessary to secure EMA regulatory approval. In the event the budget exceeds $20 million Nico Innovagroup will be granted additional shares at the price of $.50/share.

4. $8 million milestone payment no later than 60 days after EMA approval of a marketing license provided the budget is not exceeded. In no case will the milestone payments be less than $4.0 million

5. This is a 15-year agreement

6. Up to 10% Royalty Fee

“We are pleased to be working with Nico Innovagroup S.r.l, a private European investor, who recognizes the important role that oral insulin will play increasing patient compliance,” said Anna Gluskin, CEO of EastGateBiotech. “We think we have found the ideal partner that can not only go after the underserved markets in the European region, but also go after the mainstream market controlled by big pharma. These entrenched relationships with big pharma are immeasurable. This sort of blanket coverage should have a profound impact on market penetration and patient compliance. The only real way existing pharmaceuticals can grow the diabetes market is through patient compliance. Studies have shown that patient compliance which results in glycemic controls is only 55%*. This means that 45% of type 2 diabetes (T2D) patients fail to achieve glycemic control and are primarily not taking their medicine as directed. With our oral insulin mouth rinse our partners feel confident that they will be able to target this non-compliant market including those with needle phobia. In general needle phobia effects over 20%** of the general population and our partners recognize the paradigm shift that will occur when oral insulin is available.”

Rose, President of EastGate said, “Our overall game plan for the global market is growth through licensing and we believe this investment validates our licensing strategy going forward. The International Diabetes Foundation estimates that 66 million people in Europe have diabetes and 41 million people have impaired glucose intolerance. This is a very serious market and our partners are resolute that after 90 years trying to come up with an oral version of insulin that the timing is perfect for a widespread rollout of the oral Insulin mouth rinse should we achieve regulatory approval. Details of our clinical development are soon to follow.”

“At Nico Innovagroup, we have been eyewitness to the effect of diabetes in the European continent,” said Nicola Commisso, CEO of the group. “The drugs today, trying to address patient compliance with a once a week injectable are grossly inadequate, and might actually have a deleterious effect on the patients. We are delighted to work with EastGate which brings a fresh new approach to treating diabetes. We are so pleased to partner with EastGate because this agreement gives us the tools to develop the distribution network throughout Europe and allows us to capitalize on long-term existing relationships in manufacturing and distribution.”

About EastGate Biotech

EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increases the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. EastGate’s wholly owned subsidiary Omni Surgery and Anti-Aging Centre is the first of many surgery centers to come under the Omni umbrella as we plan to roll up existing business under the Omni brand and expand our footprint globally.

About Nico Innovagroup

Nico Innovagroup S.r.l. (www.nicoinnovagroup.com) is an Italian innovative start-up that operate in the healthcare and biotech field with a diversified approach and activities in genomics, pharma, precision and regenerative medicine, IVD and medical devices, both directly and through related and subsidiary companies.

The company is now incorporating the subsidiary Nico Innovapharma S.r.l., which was specifically conceived for the purpose of joint development with EastGate Biotech, and is signing cooperation and distribution agreements with mid-sized European pharmaceutical companies that will be responsible for activities in each European country.

*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966497/
**http://www.needlephobia.com/prevalence.html

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbor” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words “anticipates,” “plans,” “expects,” “indicate,” “intend,” “scheduled,” “estimates,” “forecasts,” “focus,” “guidance,” “initiative,” “model,” “methodology,” “outlook,” “potential,” “projected,” “pursue,” “strategy,” “study,” “targets,” or “believes,” or variations of or similar such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” or “should,” “might,” or “way forward,” “will be taken,” “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com

SOURCE: EastGate Biotech Corp.

ReleaseID: 510737

VANCOUVER, BC / ACCESSWIRE / August 27, 2018 / Midnight Sun Mining Corp. (the “Company” or “Midnight Sun”) (TSX-V: MMA) is pleased to report initial results of its Phase One 2018 exploration program on its Zambian copper-cobalt properties, the Solwezi Group of Licences (“Solwezi Licences”) located in the North-Western province of Zambia. Phase One work included 7 diamond drill holes totalling 1,503 meters and 234 air core holes totalling 10,424 meters at the Mitu target, as well as ground and airborne geophysical surveys.

The Company has received independent assay results for all submitted diamond drill holes. Significant results from the diamond drill holes, as well as from air core drilling are presented in the Table below.

Phase One – Mitu Area – Initial Significant Drill Hole Intercepts

Hole #

Drill Type

Mitu Area

Az

Dip

From (m)

To (m)

Interval (m)

Cu %

Co %

Ni %

Cu Eq %

MTDD035

Including

HQ Core

Discovery

035

60

115.0

125.0

129.3

129.3

14.3

4.3

0.42%

0.51%

0.10%

0.28%

0.05%

0.11%

1.61%

3.73%

MTDD036

HQ Core

Discovery

035

60

185.0

190.0

5.0

0.25%

0.04%

0.08%

0.87%

MTDD037

Including

Including

HQ Core

Southeast

035

60

129.9

129.9

146.0

153.6

135.0

147.0

23.7

5.1

1.0

0.34%

0.64%

1.62%

0.04%

0.04%

0.10%

0.15%

0.32%

1.50%

1.11%

1.81%

6.05%

MTDD038

Including

HQ Core

Southeast

035

60

101.8

104.0

123.0

111.0

21.2

7.0

0.28%

0.45%

0.05%

0.07%

0.03%

0.04%

0.88%

1.28%

MTAC198

Including

Air Core

Northwest

vertical

3.0

18.0

6.0

31.5

3.0

13.5

0.04%

0.22%

0.06%

0.05%

0.04%

0.05%

0.81%

0.81%

MTAC204

Including

Air Core

Northwest

vertical

1.5

3.0

49.5

24.0

48.0

21.0

0.14%

0.15%

0.07%

0.10%

0.05%

0.06%

0.96%

1.36%

MTAC212

Air Core

Northwest

vertical

3.0

12.0

9.0

0.03%

0.03%

0.06%

0.45%

MTAC224

Air Core

Southeast

vertical

19.5

28.5

9.0

0.05%

0.02%

0.04%

0.33%

MTAC236

Air Core

Southeast

vertical

45.0

52.5

7.5

0.05%

0.01%

0.05%

0.28%

Notes:

Reported intervals are the downhole widths, which are similar to the true widths.
Reported intervals are calculated for zones assaying > 0.2% copper or 0.02% cobalt and containing less than 2 meters of internal waste.
Copper equivalent values are estimated using current metal prices of $2.73/lb copper, $29.26/lb cobalt, and $6.03/lb nickel and are presented for ease of interval comparison only. Metallurgical recovery factors are assumed to be 100% although the recovery factors for various metals may vary significantly.

Diamond Drill Program

Drill holes MTDD035 and MTDD036 were drilled along a profile within the “Discovery Zone” established in prior years’ drilling. Drill holes MTDD037 and MTDD038 were drilled 300 meters to the southeast where one hole drilled in 2017 had defined the southeast margin of the “Discovery Zone.” These holes indicate continuity of significant copper-cobalt-nickel mineralization between previous holes.

Drill holes MTDD039 and MTDD041 tested targets to the northwest and southeast of the Discovery Zone identified by geophysical, soil geochemical and air core drill results. These holes encountered barren lithologies suggesting structural dislocation in these areas. Follow-up drilling is planned to determine the source of these anomalies.

The above drilling has shown that the Discovery Zone has a strike length of over 800 meters and a down dip extension of 300 meters.

Drill hole MTDD040 tested a prominent geophysical anomaly 5 kilometers to the southeast of the Discovery Zone, identified by geophysical work conducted in 2018. This hole did not return significant metal values, although it did encounter black shales, which are the typical host rocks for the targeted mineralization and follow up drilling in this area is planned.

Air core program

234 Air Core holes totalling 10,424 meters have been drilled in 2018, with samples being sent for independent assays on 99 of these holes with results received from 35 of these holes to date. The primary purpose of this drilling was to locate areas of black shale lithology with elevated base metal values beneath overburden to direct diamond drilling along the >14 km of indicated strike length of the Mitu trend along the western flank of the Solwezi Dome. Air Core holes also provide indications of possibly exploitable oxide mineralization within the overburden.

A map of the 2018 drill locations can be found on the company website here.

Geophysical Survey

While the Mitu area has limited surface rock exposure, the favourable black shale host rock has demonstrated a response to Natural Sourced Audio Magneto Tellurics (“NSAMT”) geophysics. The anomalies detected by this system have proven important in developing targets and directing drill holes, as the NSAMT data shows some of the structural fabric of the bedrock geology and black shale units. In 2018, an additional 34 line kilometers of NSAMT surveying have been conducted over the Mitu area and results from this work are currently being analyzed and interpreted.

In addition, a 3,889 line kilometer geophysical airborne survey was flown over the entire Solwezi License area by Geotech Airborne. The survey included the contractor’s proprietary Versatile Time-Domain Electromagnetic (“VTEM”) system, as well as horizontal magnetic gradiometer and radiometrics instruments. The VTEM system is ideal for rapid mapping of conductive units, such as the prospective black shales that host mineralization at Mitu. This will help identify black shale basins that may be similar to the Discovery Zone. The magnetics survey will help with structural mapping, as it responds to the subtly different magnetic signatures of the rocks and the typically lower magnetic signature of faults. The system should also respond to pyrrhotite, which is associated with copper-cobalt mineralization. Finally, radiometrics has proven very useful in identifying the different lithologies and will, therefore, along with the magnetics and VTEM, help generate an accurate geology map.

Once the resulting data has been received and compiled, the interpretation will guide the next phase of drilling at Mitu and other target areas including Dumbwa, Kifubwe, 22 Zone and Khaziba where significant mineralization has been encountered in previous exploration campaigns.

The Company’s President and Chief Executive Officer, Brett Richards stated: “The results of Phase One drilling continue to support the potential size and scale of the mineralization at Mitu while also showing the continuity of mineralization in the Discovery Zone. I am excited to receive the full interpretation of the geophysical work to pair with these assay results as we plan for Phase Two of this year’s exploration.”

Qualified Control/Quality Assurance

Samples obtained during both diamond drill and air core drilling were transported directly to SGS Inspection Services in Kalulushi, Zambia by Midnight Sun personnel for sample preparation. There the samples were sorted, dried, crushed, and pulped before final chemical analysis using ICP-OE methods. All samples returning >10,000 ppm Cu were automatically re-assayed for higher level concentrations by SGS, which is a fully accredited laboratory. Standards and blanks were inserted regularly in the sample stream and checks were done for Au and Cu.

Qualified Person: Peter Flindell, MAusIMM and MAIG, a Qualified Person under NI 43-101, has reviewed and approved the technical data and contents of this release.

Please refer to the Company’s previous New Releases as well as the Company presentation on its website at: www.midnightsunmining.com.

ABOUT MIDNIGHT SUN MINING

Midnight Sun has earned a 60% interest in the Solwezi Licences with the potential to acquire the remaining 40%. The Solwezi Licences are comprised of two individual prospecting licences totalling 506 square kilometres, situated in the North-Western Province of Zambia, adjacent to First Quantum’s Kansanshi Mine; Africa’s largest copper mining complex, on the prolific Zambia-Congo Copper Belt.

Led by experienced directors and talented management, Midnight Sun aims to further explore the impressive mineralization and anomalies that have recently been discovered on the Solwezi Licenses.

Midnight Sun Mining Corp. trades on the TSX Venture Exchange under the symbol MMA.

ON BEHALF OF THE BOARD OF MIDNIGHT SUN MINING CORP.

Brett A. Richards – President and Chief Executive Officer

For Further Information Contact:

Brett A. Richards Al Fabbro

President and Chief Executive Officer Lead Director

Tel: +1 905 449 1500 Tel: +1 604 351 8850

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEW RELEASE.

This news release includes certain statements that may be deemed “forward-looking statements.” All statements in this release, other than statements of historical facts, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include changes in market conditions, unsuccessful exploration results, changes in commodity prices, unanticipated changes in key management personnel and general economic conditions. Mining exploration and development is an inherently risky business. Accordingly, the actual events may differ materially from those projected in the forward-looking statements. This list is not exhaustive of the factors that may affect any of the Company’s forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company’s forward-looking statements. The Company does not undertake to update any forward-looking statement that may be made from time to time by the Company or on its behalf, except in accordance with applicable securities laws.

SOURCE: Midnight Sun Mining Corp.

ReleaseID: 510735

JACKSON CENTER, PA / ACCESSWIRE / August 27, 2018 / Premier Biomedical, Inc. (OTCQB: BIEI) (the “Company”) announced President and CEO, William A. Hartman’s interview on Uptick Newswire’s “Stock Day” Podcast.

Everett Jolly began the interview by welcoming back Premier Biomedical, Inc. President and CEO, William A. Hartman for a Company update since July 2018. Jolly stated that he still thinks this Company is undervalued even after their 250:1-split. Jolly asked Hartman to give his listeners information about their latest developments.

Hartman got right to the point. Premier Biomedical has recently formed an agreement with ex-Army purchasing group called “4 Your Pain.” This group has taken on the task of introducing Premier Biomedical’s CBD topical pain relief products to the military and to the government as an alternative to dangerous and addictive opioid pain medications. The Company’s goal is to be the primary source for all pain medications for the military and the governmental agencies.

Hartman added,”What is driving the market explosion of our superior topical pain relief products is the fact that almost 200 people per day are dying from drug overdoses, and a recent study concluded that almost 70% of those people started on opioid pain medications. This is a real opioid crisis in this country.”

Premier Biomedical primary focus is the manufacture and distribution of all-natural, 50-state legal, pesticide-and solvent-free hemp oil-based pain management products, including 96-hour pain relief patches, roll-on applicators, ointments, and pump sprays sold on the Company’s website at www.painreliefmeds.com and at select pharmacies and doctors’ offices.

Jolly wanted to know what makes the Company’s products so special. Hartman indicated that it was a combination of things, including a unique formulation and products containing more much CBD than the competition. Their new line of Extra Strength “Pain-Ex II ™” products have even more CBD than the competition at market prices That means real pain relief, which is what people suffering from pain are seeking.

Premier Biomedical also has recently re-organized their industry-leading technologies in their separate Biologics Division. The Company recently placed these on-the-shelf technologies into separate centers of expertise, providing specific technology investors assurance of focused use of funds without diluting the Company’s stock. The Company announced this as a win for technology investors and a win for stockholders.

Jolly asked what listeners should take away from this interview. Hartman said the biggest thing we have coming is a potential near-term joint venture, which will help expand the Company dramatically. He can’t say any more because it’s not finalized, but this is just a teaser for your podcast listeners.

Hartman concluded, “We’re a Company about change. We’re a Company about responding to the market and responding to our investors. We have experienced many challenges, but we have erupted from them even stronger than ever. I see a brilliant future for this Company!” Hartman stated that he looks forward to returning to the podcast in the near future with another exciting update.

For more information about the Company’s financial details, listen to the full interview at the link below.

http://www.premierbiomedical.com/wp-content/uploads/2018/08/Uptick-Podcast-27-Aug-18.mp3

About Premier Biomedical, Inc. (BIEI):

Premier Biomedical, Inc., is in part a research-based company that primarily intends to discover and develop medical products. Our current focus is on the distribution of our pain management products. Our current pain management products are made from hemp oil extracts and include roll-on applicators, pain relief patches, creams and pump spray applicators. We also conduct research and development of proprietary drugs and techniques to target PTSD, cancer, anti-aging, multiple sclerosis and other diseases. Visit their website at www.premierbiomedical.com

Contact:

Premier Biomedical, Inc.
P.O. Box 25
Jackson Center, PA 16133
(814) 786-8849
http://www.premierbiomedical.com/
info@premierbiomedical.com
https://painreliefmeds.com/

Safe Harbor Act and Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors is contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/

Uptick Newswire
https://upticknewswire.com/

SOURCE: Premier Biomedical, Inc.

ReleaseID: 510728

VANCOUVER, BC / ACCESSWIRE / August 27, 2018 / MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) is pleased to announce that joint-venture partner Belmont Resources (BEA) has reported that drilling has reached a depth of 1,798 feet (548 metres) into the playa sediments in hole KB-3, the first hole of the 2018 drilling program at Kibby Basin. The first section of the hole was drilled to a depth of 1,270 feet using a mud rotary method, and the remaining 528 feet was completed with a diamond core tail. A total of 126 samples of drill cuttings from the mud-rotary section of the hole have been collected and shipped to ALS Global lab facility in Reno, Nevada for assaying. Lithium and multi-element assay results from these samples will be compiled once testing is complete.

The borehole targeted the southern portion of a large MT conductor, which may represent saturated sediments containing lithium brine. The hole drilled through lacustrine playa sediments – dominantly calcareous clays and silts grading to lithified claystone’s and siltstones at depth. Sand and gravel zones, which may represent brine-bearing aquifers, were encountered at depths of 150-170 feet, 210-230 feet, 260-300 feet, and 900-920 feet, where a potential aquifer in a cobble gravel was intersected.

Oxidized clay zones at 400-640 feet and several thinner zones of clay deeper in the hole are being evaluated as potential lithium-bearing bedrock mineralization. Thin intervals of altered rhyolite ash and possible hot-spring sinter were encountered at 1411-1412 feet, 1488-1490 feet and 1589.5-1590 feet. Operation of a paleo-geothermal system is evidenced by the silicified intervals and fronts of pyrite and magnetite alteration increasing below a depth of 1500 feet.

A down-hole geophysical survey including gamma-caliper-temperature-fluid resistivity and SP, SPR logging will be conducted on the hole to identify permeable aquifer zones and conductive brine zones. Water samples will be collected after the geophysical logging, and will be assayed for lithium, associated elements and physical properties. Sections of drill core from 1270 to 1798 feet will be split and similarly assayed as above.

About the Kibby Basin Lithium Brine Partnership

MGX is partnered with Belmont Resources (BEA) on the Property and currently earning a 50% interest with the goal of forming a 50/50 Joint Venture (the “Joint Venture”) to utilize MGX’s rapid lithium extraction technology. Kibby Basin is located in the western portion of the Great Basin in Nevada. The property covers 2,560 acres located in Esmeralda County, Nevada. Kibby Flat is a dry playa and no springs or water sources occur on the Property. Geothermal research by the Nevada Bureau of Mines and Geology (“NvBMG”) identified three wells and springs in the region. All three sources indicated near-surface water. Nevada has abundant geothermal resources and NvBMG compilation has outlined areas with potential heat flow, based on surface temperatures of springs, drill hole-water temperatures, geothermal-related geochemical signatures, and associated geologic settings. These areas suggest zones of potential elevated heat flow.

Geologic research of the Kibby Basin has indicated that proximal rhyolitic flows and tuffs surrounding the basin could be a potential source of Li brine in the Kibby Basis Playa. In addition, the Kibby Basin is located within a geothermal cluster at a basin low setting. Regional geophysical signatures in the area reflect similar anomalies comparative to that of Clayton Valley, approximately 50km to the South, location of Abermarle’s Silver Peak Mine, the only North American lithium producer.

Rapid Lithium Brine Extraction Technology

MGX has developed a rapid lithium extraction technology eliminating or greatly reducing the physical footprint and investment in large, multi-phase, lake-sized, lined evaporation ponds, as well as enhancing the quality of extraction and recovery across a complex range of brines as compared with traditional solar evaporation. This technology is applicable to petrolithium (oil and gas wastewater), natural brine, and other brine sources such as lithium-rich mine and industrial plant wastewater. The technology was recently chosen as winner of the Base and Specialty Metals Industry Leadership Award at the 2018 S&P Global Platts Global Metals Awards, held in London in May (see press release dated May 18, 2018).

About the Kibby Basin Lithium Joint Venture

MGX will acquire a 25% interest in the Project by spending $300,000 on exploration and 50% by incurring an additional $300,000 in exploration expense at which time the project will become a 50/50 Joint Venture. Upon formation of a Joint Venture, MGX will become the Project operator and can elect to conduct additional exploration drilling, well testing operations, and extraction plant installation. Additionally, MGX will provide access to its rapid lithium extraction technology (see press release dated July 13, 2018).

Qualified Person

Andris Kikauka (P. Geo.), Vice President of Exploration for MGX Minerals, has prepared, reviewed and approved the scientific and technical information in this press release. Mr. Kikauka is a non-independent Qualified Person within the meaning of National Instrument 43-101 Standards.

About MGX Minerals

MGX Minerals is a diversified Canadian resource company with interests in advanced material and energy assets throughout North America. Learn more at www.mgxminerals.com.

Contact Information

Jared Lazerson
President and CEO
Telephone: 1.604.681.7735
Web: www.mgxminerals.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements (collectively “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is typically identified by words such as: “believe,” “expect,” “anticipate,” “intend,” “estimate,” “potentially” and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors. The reader is referred to the Company’s public filings for a more complete discussion of such risk factors and their potential effects which may be accessed through the Company’s profile on SEDAR at www.sedar.com.

SOURCE: MGX Minerals Inc.

ReleaseID: 510736

TEL-AVIV, ISRAEL / ACCESSWIRE / August 27, 2018 / Blockchain based mobile advertising protocol Zinc, founded by a group of industry pros with proven mobile advertising experience, aims to build a next-gen advertising ecosystem, where the user is an active player rather than a commodity, while allowing everyone in the industry to continue operating as they do now, re-allocating millions in wasted advertising spend.

Zinc is a user-centric advertising protocol that will allow advertisers & ad networks to reward users for sharing their information and viewing ads.

From the user perspective, Zinc is offering the security, decentralization, and transparency users have come to expect from blockchain based technology stacks. From the advertisers, ad networks and publishers’ perspective – Zinc will offer a new way to reward users for sharing their information, as well as enable GDPR compliance, while allowing them to continue to perform business as usual with a unique payment flow.

Zinc is poised to solve two main challenges the mobile ad industry faces: fraud and data inefficiencies. In mobile advertising’s current state, nobody wins. Advertisers are frustrated due to ineffective targeting caused by bad data & fraudulent activity, and this limitation in targeting capabilities forces them to centralize their budgets with monopolistic players, such as Google and Facebook.

As Daniel Trahtemberg, Zinc Protocol CEO & Co-Founder, explains:

“The Zinc Protocol allows users to get what they really want: more rewards while viewing less ads – creating a better user experience. Zinc provides first party, verifiable data, and allows advertisers to target real humans who agreed to share their data, allowing us to mitigate a significant amount of fraud”

The wallet application will be launched end of Q3 2018, and once the wallet application is launched, it will allow users to get Zincs and get more rewards for ads they are already seeing, in the apps they already use – from day one. The Zinc app will be distributed via the Rewarded Video (RV) channel, reaching out to users who are accustomed to being rewarded for viewing ads, and will want to maximize the in-app perks they get.

Leading mobile monetization and marketing company ironSource is a main design partner of the Zinc protocol. ironSource reaches over 1.5 billion unique active users monthly through their SDK, which is integrated on tens of thousands of the world’s most popular apps.

Contact:

Dan Edelstein
pr@marketacross.com
+972-545-464-238

SOURCE: ironSource

ReleaseID: 510759